Andrew X. Zhu, MD, PhD
Second-line ramucirumab (Cyramza) reduced the risk of death by 29% versus placebo in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP), according to results from the phase III REACH-2 trial presented at the 2018 ASCO Annual Meeting.1
The median overall survival (OS) was 8.5 months with ramucirumab versus 7.3 months with placebo (HR, 0.710; 95% CI, 0.531-0.949, P
= .0199) among patients with progression on or intolerance to first-line treatment with sorafenib (Nexavar). Survival in both groups exceeded statistical assumptions of the trial design (4.7 months with placebo, improved to 6.5 months with ramucirumab).
... to read the full story